

Wednesday, October 5, 2016			
12:00-5:00	Registration		
2:00-6:00	Symposium on Advances in Multiple Myeloma Chair: Pieter Sonneveld (Netherlands) and Kenneth C. Anderson (USA)		
2:00	Nikhil Munshi	USA	How can we use genomic sequencing to understand therapy related clonal evolution in multiple myeloma?
2:30	Ola Landgren	USA	What are the lessons learned for evaluating depth of response in myeloma?
3:00	Pieter Sonneveld	Netherlands	Should carfilzomib or ixazomib represent the new standard for proteasome inhibitor therapy in myeloma?
3:30	Meletios Dimopoulos	Greece	Where do monoclonal antibodies fit into the treatment strategy for myeloma?
4:00	Niels van de Donk	Netherlands	How can we improve monoclonal antibody efficacy in myeloma?
4:30	Bart Barlogie	USA	Do we still need autologous transplants in the era of novel therapeutics?
5:00	Kenneth Anderson	USA	Does myeloma have an Achilles heel?
5:30	Discussion Session		
6:00-8:00	IWWM9 Welcome Reception		
Thursday, October 6, 2016			
Session 1	Diagnostic Workup of WM		Chair: Ramón García Sanz (Spain)
8:00	Roger Owen	UK	What are the updated diagnostic and response criteria in WM?
8:15	Xavier Leleu	France	Can molecular markers help in the diagnosis and management of WM?
8:30	Ramón García Sanz	Spain	Does MYD88 status impact disease presentation and outcome?
8:45	Robert A Kyle	USA	When is treatment appropriate in WM?
9:00	Discussion Session		
9:30	Coffee/Tea Break		
Session 2	Predisposition in WM		Chair: Ola Landgren (USA)
10:00	Mary McMaster	USA	Are there familial aggregation patterns that associate with increased risk of WM?
10:15	Irene Ghobrial	USA	Are there genomic alterations that associate with familial WM?
10:30	Sigurdur Kristinsson	Iceland	Does familial disease impact prognosis and treatment outcome in WM?
10:45	Douglas Joshua	Australia	Do defects in T-cell immunity contribute to disease progression in plasma cell disorders?
11:00	Discussion Session		
Session 3	Malignant Transformation in WM		Chair: Linda Pilarski (Canada)
11:30	Bruno Paiva	Spain	What phenotypic and genomic changes define transformation from IgM MGUS to symptomatic WM?

11:45	Christina Jimenez	Spain	Does the mutational landscape change with evolution of IgM MGUS to active WM?
12:00	Alessandra Trojani	Italy	Does transcriptome-wide analysis demonstrate significant differences in gene expression variability between WM and IgM MGUS BM B cell clones?
12:15	Linda Pilarski	Canada	Clonal complexity in WM and potential therapeutic options.
12:30	Lunch Break		
Session 4	Genomic Landscape in WM		Chair: Nikhil Munshi (USA)
1:30	Zachary Hunter	USA	What are the key findings from genome and transcriptome profiling in WM?
1:45	Ruben Carrasco	USA	Is MYD88 alone sufficient to induce a malignant phenotype?
2:00	Stephanie Poulain	France	What is the genomic landscape of CXCR4 mutations in WM?
2:15	Nikhil Munshi	USA	Why is subclonal evolution important to the study of WM?
2:30	Discussion Session		
3:00	Coffee/Tea Break		
Session 5	Plenary Talks		Chair: Pierre Morel (France) and Marvin Stone (USA)
3:30	Lian Xu et al	USA	Molecular basis of ibrutinib resistance in WM.
3:45	M. Varettoni et al	Italy	CXCR4 mutations are associated with more advanced disease and shorter time to first treatment in patients with WM.
4:00	Ruth de Tute et al	UK	Evaluation of a WM-specific flow cytometry assay for diagnosis and disease response assessment.
4:15	Damien Roos-Weil et al	France	Characterization of molecular abnormalities in WM.
4:30	Rebecca Auer et al	UK	R2W: Subcutaneous BCR versus FCR for initial therapy of WM: a randomized phase II study.
4:45	Day Highlights (Monique Minnema, Workshop Co-Chair)		
7:00-11:00	Opening Ceremonies: Westerkerk Robert A. Kyle Award Ceremony		
Friday, October 7, 2016			
Session 6	Keynote Lectures: Myddosome Signaling: What have we learned?		Chair: Claudio Sette (Italy)
8:00	Guang Yang	USA	What drives mutated MYD88 pro-survival signaling in WM?
8:15	Roman Jerala	Slovenia	How do MYD88 mutations contribute to constitutive pro-survival signaling?
8:30	Frank Peelman	Belgium	What are the critical residues within MYD88 that contribute to Myddosome signaling?
8:45	Claudio Sette	Italy	Can Myddosome assembly be targeted as a treatment strategy?

9:00	Discussion Session		
9:30	Coffee/Tea Break		
Session 7	CXCR4 WHIM mutations and WM Pathogenesis		Chair: Zachary Hunter (USA)
10:00	Lian Xu	USA	What implications does the clonal architecture of CXCR4 mutations have for WM pathogenesis?
10:15	Janine Schmidt	Germany	Do CXCR4 mutations impact disease presentation in WM?
10:30	Aldo Roccaro	Italy	What are the functional consequences of CXCR4 WHIM mutations in WM?
10:45	Shih-Shih Chen	USA	What role does BTK play in CXCR4 signaling?
11:00-11:30	Special Lecture: Stefania Scala (Italy)	How can we target the CXCL12-CXCR4 axis in oncology patients?	
11:30	Discussion Session		
12:00	Lunch Break and ECWM Meeting (For Invited Faculty)		
Session 8	Non-MYD88 and CXCR4 Signaling in WM		Chair: Steven T. Pals (Netherlands)
1:30	Kimon Argyropoulos	USA	Does aberrant BCR signaling contribute to WM survival signaling?
1:45	Steven T Pals	Netherlands	Does BCR signaling impact micro-environmental interactions in WM?
2:00	Christian Reinhardt	Germany	Is BCL2 expression critical for mutated MYD88 oncogenesis?
2:15	Stephen Ansell	USA	What regulates IgM secretion in WM?
2:30	Discussion Session		
Session 9	BTK directed Therapy in WM		Chair: Meletios Dimopoulos (Greece)
3:00	M. Lia Palomba	USA	Ibrutinib in previously treated WM patients: Update of PFS and OS Data.
3:15	Meletios Dimopoulos	Greece	Ibrutinib in rituximab refractory WM patients.
3:30	Steven Treon	USA	Somatic Variants that contribute to ibrutinib resistance in WM.
3:45	Constantine Tam	Australia	BgB-3111 in previously treated WM patients.
4:00	Discussion Session		
4:30	Day Highlights (Steven T Pals, Workshop Co-Chair)		
Session 10	Poster Viewing Reception and Short Oral Presentations of Selected Abstracts		Chairs: Enrica Morra (Italy) and Veronique Leblond (France)
5:00-6:30	Short Oral Presentations		
5:30	Simone Ferrero et al	Italy	MYD88 L265P mutation detection in WM by droplet digital PCR minimal disease monitoring and characterization on circulating free DNA.
5:40	L Kaiser et al	Germany	Characterization of endogenous CXCR4 inhibitory peptides to target WM.
5:50	JJ Castillo et al	USA	Ixazomib, dexamethasone and rituximab (IDR) as primary therapy for symptomatic WM.
6:00	Xia Liu et al	USA	HCK transcription is regulated by AP1, NK-kB and STAT3 transcription factors in MYD88 mutated WM and ABC-

			DLBCL cells.
6:10	ML Guerrero et al	Italy	Chromosome 6q deletions are common in WM, and target regulatory genes for MYD88, CXCR4 and BCL2 signaling.
6:20	Eric Durot et al	France	Retrospective analysis of 56 cases of transformed WM.
Saturday, October 8, 2016			
Session 11	Novel Therapeutic approaches for WM		Chair: M.J. Kersten (Netherlands)
8:00	Matthew Davids	USA	What should we expect from BCL-2 inhibitors in the management of WM?
8:15	Steven Ansell	USA	Do checkpoint inhibitors offer a novel therapeutic strategy in WM?
8:30	Kenneth Anderson	USA	Could monoclonal antibodies targeting plasma cells benefit WM patients?
8:45	David Maloney	USA	Is CAR T-cell immunotherapy appropriate for WM patients?
9:00	Discussion Session		
9:30	Coffee/Tea Break		
Session 12 10:00-12:30	<p>Great Debate I: What should be the frontline standard for treatment of WM? (10 min presentation, 5 min rebuttal) Moderator: Christian Buske (Germany)</p> <p><u>Overview:</u> Do frontline treatments for WM reflect regional economics and practice patterns? Christian Buske (Germany)</p> <p>Should Bendamustine be the standard for frontline treatment of WM? Mathias Rummel (Germany)</p> <p>Should Cyclophosphamide based therapy (CDR) be the standard for frontline treatment of WM? Evangelos Terpos (Greece)</p> <p>Should Nucleoside analogues be the standard for frontline treatment of WM? Veronique Leblond (France)</p> <p>Should proteasome inhibitors be the standard for frontline treatment of WM? Jorge Castillo (USA)</p> <p>Should ibrutinib be the standard for frontline treatment of WM? Meletios Dimopoulos (Greece)</p>		
	<p>Great Debate II: What should be the goal of therapy in 2017 for WM patients? Moderator: Eva Kimby (Sweden) (10 min presentation, 5 min rebuttal)</p> <p><u>Overview:</u> Why are complete responses so uncommon in WM? Eva Kimby (Sweden)</p>		

	Complete response should be the goal of therapy for WM patients in 2017 Alessandra Tedeschi (Italy)		
	Disease control should be the goal of therapy for WM patients in 2017 Efsthatis Kastritis (Greece)		
12:30	Lunch		
Session 13	Management of Specific Disease Morbidities in WM (Part 1)		Chair: Monique Minnema (Netherlands)
1:30	Shirley D'Sa	UK	What is the optimal treatment for the WM/IgM MGUS patient with peripheral neuropathy?
1:45	Monique Minnema	Netherlands	What is the appropriate work-up and management of the WM patient with Bing Neel syndrome?
2:00	Josephine Vos	Netherlands	How should renal failure be worked up on a WM patient, and how does it impact care and outcome?
2:15	Discussion Session		
2:30	Coffee/Tea Break		
Session 14	Management of Specific Disease Morbidities in WM (Part 2)		Chair: Giampaolo Merlini (Italy)
3:00	Ashutosh Wechalekar	UK	Do patients with IgM related disorders have a different amyloid presentation and course?
3:15	Giampaolo Merlini	Italy	What is the optimal work-up and treatment approach for the WM patient with amyloidosis?
3:30	Marvin Stone	USA	How should patients with symptomatic hyperviscosity and cryoglobulins be managed?
3:45	Discussion Session		
Session 15	Discussion: When should autologous transplant be offered to WM patients?		Chair: Chara Kyriakou (UK)
4:00	Chara Kyriakou	UK	Overview: What do we know about ASCT efficacy in WM?
4:15	Bart Barlogie	USA	Autotransplants should be offered early!
4:30	JP Fermand	France	Autotransplants should be offered later, perhaps, never!
4:45	Discussion Session		
5:00	Day Highlights (M.J. Kersten, Workshop Co-Chair)		
7:00-11:00	Scheepvaartsmuseum Dinner Reception and Closing Ceremonies Special Guest Speaker: Edvard Smith, Karolinska University, Sweden Waldenström Award Ceremony, Welcome by IWWM10 Organizers		